Media releases are provided as is by companies and have not been edited or checked for accuracy. Any queries should be directed to the company itself.
  • 7 December 2020 23:19

Viral Vectors and Plasmid DNA Manufacturing Market to Attain Valuation USD 1.3 Billion by 2027

The global viral vectors and plasmid DNA manufacturing market size was valued at USD 319.01 million in 2019 and expected to reach USD 1.3 billion by 2027, growing at a compound annual growth rate (CAGR) of 14.08% during period 2020 to 2027.

The global viral vectors and plasmid DNA manufacturing market report offers various segments analysis by size, trends, growth factors, opportunities and key country outlook to 2027. The report offers a detailed analysis and information as per viral vectors and plasmid DNA manufacturing manufacturers, market segments helping our readers to get a comprehensive overview of the global market. Several players are planning to focus on developing cost-effective products or services, aiming to maintain a strong foothold in the market.

The company profiling of leading market players is included this report with Porter's five forces analysis and Value Chain analysis. Further, the strategies exercised by the companies for expansion of business through mergers, acquisitions, and other business development measures are discussed in the report. The financial parameters which are assessed include the sales, profits and the overall revenue generated by the key players of Market.

Growth Factors

Viral vectors have become ideal choice for gene transfer due to their efficient gene delivery, high transfection efficiency and stable gene expression. Further, upsurge in registration of clinical trials on viral vector-mediated gene therapy is stimulating inclination for viral vectors in gene transfer. Growing pervasiveness of target disorders and diseases, the accessibility of funding for gene therapy development, current research into viral vector-based cell and gene therapies and efficacy of viral vectors in gene therapy delivery are together supporting the market growth. Unexploited latent in emergent markets is projected to provide worthwhile growth opportunities for participants in this market. Furthermore, groundbreaking development in the vaccinology is fuelling the demand of these vectors to greater extent. Great amount of clinical and preclinical studies assessing the prospective of vectors in these cutting-edge therapies have exhibited favorable results. As a result of this, several investors are attracted towards this area which is making plasmid and viral vector manufacturing market a vigorous sector of investment. Further, it is inspiring fortunate funding activities from both the public and private sectors.

Ask here for more information@ https://www.precedenceresearch.com/customization/1012

Report Highlights

- Presently, around two-thirds of the gene therapy research is dedicated to oncology. These different facts have backed the governance of cancer segment over other disease segments

- Extensive progress made in gene and cell therapy research since the early 1970s and 1980s has accelerated the adoption rate of plasmids and viral vectors for their use in these modern therapies

- Pharmaceutical and biopharmaceutical companies are expected to collect major share of the global vector market. This is because of the effective launch of viral vector gene therapies and a vigorous pipeline of such therapies that helps growth of pharmaceutical and biopharmaceutical companies during near future.

- Presently, U.S. and Europe have seemed as vector manufacturing centers despite of the fact that the first 3 gene therapy candidates were granted in Asian countries

Report Analyzes Market Opportunity By Following Region Regional Market Overview:

- North America (the United States, Canada and Mexico)

- Europe (Germany, UK, France, Italy, Russia and Turkey, etc.)

- Asia-Pacific (China, Japan, Korea, India, Australia and Southeast Asia (Indonesia, Thailand, Philippines, Malaysia, and Vietnam))

- South America (Brazil etc.)

- The Middle East and Africa (North Africa and GCC Countries)

Regional analysis is another highly comprehensive part of the research and analysis study of the global market presented in the report. This section sheds light on the sales growth of different regional and country-level markets. For the historical and forecast period to 2027, it provides detailed and accurate country-wise volume analysis and region-wise market size analysis of the global market.

Highlights of the Report:

- Market Penetration: Comprehensive information on the product portfolios of the top players in the Supply Chain Analytics market.

- Product Development/Innovation: Detailed insights on the upcoming technologies, R&D activities, and product launches in the market

- Competitive Assessment: In-depth assessment of the market strategies, geographic and business segments of the leading players in the market

- Market Development: Comprehensive information about emerging markets. This report analyzes the market for various segments across geographies

- Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the Supply Chain Analytics market

Purchase this Premium Research Report@ https://www.precedenceresearch.com/checkout/1012

Some of the significant players in the viral vectors & plasmid DNA manufacturing market include:

  • Novasep
  • Aldevron
  • MerckWaismanBiomanufacturing
  • Creative Biogene
  • The Cell and Gene Therapy Catapult
  • Cobra Biologics
  • uniQure N.V.
  • Addgene
  • FUJIFILM Holdings Corporation
  • Oxford Biomedicaplc
  • Takara Bio Inc.

Market Segmentation

By Vector Type

  • Adenovirus
  • Plasmid DNA
  • Lentivirus
  • Retrovirus
  • AAV
  • Others
By Application
  • Gene Therapy
  • Antisense &RNAi
  • Cell Therapy
  • Vaccinology
By Workflow
  • Upstream Processing
    • Vector Recovery/Harvesting
    • Vector Amplification & Expansion
  • Downstream Processing
    • Fill-finish
    • Purification
By End-User
  • Biopharmaceutical and Pharmaceutical Companies
  • Research Institutes
By Disease
  • Genetic Disorders
  • Cancer
  • Infectious Diseases
  • Others
By Geography
  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • France
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
  • Rest of the World

Research Methodology

Secondary Research

It involves company databases such as Hoover's: This assists us recognize financial information, structure of the market participants and industry competitive landscape.

The secondary research sources referred in the process are as follows:

- Governmental bodies, and organizations creating economic policies

- National and international social welfare institutions

- Company websites, financial reports and SEC filings, broker and investor reports

- Related patent and regulatory databases

- Statistical databases and market reports

- Corporate Presentations, news, press release, and specification sheet of Manufacturers

Primary Research

Primary research includes face-to face interviews, online surveys, and telephonic interviews.

- Means of primary research: Email interactions, telephonic discussions and Questionnaire based research etc.

- In order to validate our research findings and analysis we conduct primary interviews of key industry participants. Insights from primary respondents help in validating the secondary research findings. It also develops Research Team’s expertise and market understanding.

Industry participants involved in this research study include:

- CEOs, VPs, market intelligence managers

- Procuring and national sales managers technical personnel, distributors and resellers

- Research analysts and key opinion leaders from various domains

Submit a media release